|17.29||+0.0400||+0.23%||Vol 274.92K||1Y Perf 14.73%|
|Apr 19th, 2021 15:06 DELAYED|
|- -%||- -|
|Target Price||27.50||Analyst Rating||Strong Buy 1.38|
|Potential %||59.24||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-/-100/-100||Value Ranking||★ 40.56|
|Insiders Value % 3/6/12 mo.||-/-100/-100||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-100/-100||Income Ranking||— -|
|Market Cap||811.19M||Earnings Rating||Sell|
|Price Range Ratio 52W %||67.37||Earnings Date||5th May 2021|
Today's Price Range
5 Year PE Ratio Range
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||5th May 2021|
|Estimated EPS Next Report||-0.69|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||547.52K|
|Avg. Monthly Volume||479.54K|
|Avg. Quarterly Volume||702.98K|
Aerie Pharmaceuticals Inc. (NASDAQ: AERI) stock closed at 17.25 per share at the end of the most recent trading day (a -3.74% change compared to the prior day closing price) with a volume of 489.74K shares and market capitalization of 811.19M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 365 people. Aerie Pharmaceuticals Inc. CEO is Vicente Anido.
The one-year performance of Aerie Pharmaceuticals Inc. stock is 14.73%, while year-to-date (YTD) performance is 27.68%. AERI stock has a five-year performance of 13.86%. Its 52-week range is between 9.01 and 21.3, which gives AERI stock a 52-week price range ratio of 67.37%
Aerie Pharmaceuticals Inc. currently has a PE ratio of -4.80, a price-to-book (PB) ratio of 37.13, a price-to-sale (PS) ratio of 14.07, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -40.92%, a ROC of -48.92% and a ROE of -178.00%. The company’s profit margin is -%, its EBITDA margin is -159.80%, and its revenue ttm is $62.80 Million , which makes it $1.34 revenue per share.
Of the last four earnings reports from Aerie Pharmaceuticals Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.69 for the next earnings report. Aerie Pharmaceuticals Inc.’s next earnings report date is 05th May 2021.
The consensus rating of Wall Street analysts for Aerie Pharmaceuticals Inc. is Strong Buy (1.38), with a target price of $27.5, which is +59.24% compared to the current price. The earnings rating for Aerie Pharmaceuticals Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Aerie Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Aerie Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 19.37, ATR14 : 1.24, CCI20 : -97.26, Chaikin Money Flow : -0.09, MACD : 0.46, Money Flow Index : 49.39, ROC : -3.20, RSI : 50.54, STOCH (14,3) : 28.15, STOCH RSI : 0.00, UO : 47.40, Williams %R : -71.85), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Aerie Pharmaceuticals Inc. in the last 12-months were: Casey C. Kopczynski (Option Excercise at a value of $11 888), Casey C. Kopczynski (Sold 30 000 shares of value $390 175 ), Gerald D. Cagle (Sold 10 000 shares of value $152 700 ), Murray A. Goldberg (Option Excercise at a value of $88 200)
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.